In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Blueprint Medicines (BPMC – Research Report), with a price target of $152.00. The company's shares closed last Wednesday at $82.28, close to its 52-week low of $79.08. According to TipRanks.com, Benjamin is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.6% and a 31.9% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Blueprint Medicines with a $123.
https://www.tipranks.com/news/blurbs/jmp-securities-thinks-blueprint-medicines-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Blueprint Medicines Charts.
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Blueprint Medicines Charts.